Validation of a Set of Clinical Criteria for the Diagnosis of Secondary Progressive Multiple Sclerosis

Alin Ciubotaru1,2, Daniel Alexa1,2, Cristina Grosu1,2

  • 1Department of Neurology, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iași, Romania.

Brain Sciences
|November 27, 2024
PubMed

Insights

This study validates clinical tests for tracking multiple sclerosis (MS) progression from relapsing-remitting MS (RRMS) to secondary progressive MS (SPMS). The Romanian Society of Neurology

Area of Science:

  • Neurology
  • Clinical Research
  • Epidemiology

Background:

  • Multiple sclerosis (MS) is a chronic CNS inflammatory disease with demyelination.
  • Relapsing-remitting MS (RRMS) can progress to secondary progressive MS (SPMS).
  • Validating criteria for RRMS to SPMS progression is crucial for patient management.

Purpose of the Study:

  • To validate criteria for RRMS to SPMS progression proposed by Romanian experts against international criteria.
  • To assess the efficacy of clinical tests in identifying MS progression.

Main Methods:

  • A cohort study of 120 MS patients diagnosed via McDonald Criteria 2017.
  • Data collection included epidemiological factors and clinical tests: 9-hole peg test (9HPT), 25-foot walk test (25FWT), expanded disability status scale (EDSS), and symbol digit modalities test (SDMT).
  • Data analyzed at baseline (T0) and 12-month follow-up (T1) using statistical methods including ROC curve analysis.

Main Results:

  • Kaiser-Meyer-Olkin analysis (0.683) validated the clinical tests used.
  • ROC analysis showed EDSS, 9HPT, and 25FWT are highly sensitive for diagnosing SPMS, aligning with Spanish experts but not Karolinska.
  • Croatian expert criteria indicated only EDSS was significant for SPMS progression.

Conclusions:

  • All clinical methods are valid for identifying patients at risk of MS progression.
  • The Romanian Society of Neurology's model aligns with international expert opinions for detecting progression risk.
  • This validation supports tailored therapeutic management for SPMS.